Genetics of soft tissue tumors

Julia A. Bridge, Marilu Nelson

Research output: Chapter in Book/Report/Conference proceedingChapter

4 Citations (Scopus)

Abstract

The evolution of mesenchymal tumor classification schemes has coincided with cytogenetic and molecular advances. Increasing recognition of the specific genetic abnormalities inherent in these tumors and the growing use of cytogenetic and molecular genetic procedures have aided in the formulation of a diagnosis and the resolution of cellular origin. Several of the genetic markers are also of prognostic value, and the importance of molecular testing for guiding targeted therapeutic strategies in mesenchymal neoplasia is emerging. The objective of this chapter is to review recurrent or tumor-specific genetic events in mesenchymal neoplasms and discuss the cytogenetic and molecular cytogenetic approaches commonly used in clinical practice to identify them. GENETIC EVENTS AND MOLECULAR PATHOLOGIC APPROACHES: Three common genetic approaches used to identify mesenchymal tumor-specific abnormalities include (1) conventional cytogenetic; (2) molecular cytogenetic (fluorescence in situ hybridization [FISH]); and, (3) reverse transcription-polymerase chain reaction (RT-PCR) analyses. Historically, many of the genetic abnormalities that have come to be recognized as tumor specific in sarcomas were first identified by conventional cytogenetic analysis.1 In turn, the initial cytogenetic evidence facilitated the cloning of many candidate genes involved in the pathogenesis of mesenchymal tumors. Cytogenetic analysis has provided clinicians with a valuable tool to supplement their diagnostic armamentarium. The addition of molecular cytogenetic (FISH) and molecular approaches (RT-PCR) has further enhanced the sensitivity and accuracy of detecting nonrandom chromosomal imbalances or structural rearrangements in sarcomas, including assessment in formalin-fixed, paraffin-embedded tissues.

Original languageEnglish (US)
Title of host publicationModern Soft Tissue Pathology
Subtitle of host publicationTumors and Non-Neoplastic Conditions
PublisherCambridge University Press
Pages105-126
Number of pages22
ISBN (Electronic)9780511781049
ISBN (Print)9780521874090
DOIs
StatePublished - Jan 1 2010

Fingerprint

Cytogenetics
Neoplasms
Fluorescence In Situ Hybridization
Sarcoma
Reverse Transcription
Molecular Biology
Polymerase Chain Reaction
Cytogenetic Analysis
Genetic Markers
Paraffin
Formaldehyde
Organism Cloning
Genes

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Bridge, J. A., & Nelson, M. (2010). Genetics of soft tissue tumors. In Modern Soft Tissue Pathology: Tumors and Non-Neoplastic Conditions (pp. 105-126). Cambridge University Press. https://doi.org/10.1017/CBO9780511781049.005

Genetics of soft tissue tumors. / Bridge, Julia A.; Nelson, Marilu.

Modern Soft Tissue Pathology: Tumors and Non-Neoplastic Conditions. Cambridge University Press, 2010. p. 105-126.

Research output: Chapter in Book/Report/Conference proceedingChapter

Bridge, JA & Nelson, M 2010, Genetics of soft tissue tumors. in Modern Soft Tissue Pathology: Tumors and Non-Neoplastic Conditions. Cambridge University Press, pp. 105-126. https://doi.org/10.1017/CBO9780511781049.005
Bridge JA, Nelson M. Genetics of soft tissue tumors. In Modern Soft Tissue Pathology: Tumors and Non-Neoplastic Conditions. Cambridge University Press. 2010. p. 105-126 https://doi.org/10.1017/CBO9780511781049.005
Bridge, Julia A. ; Nelson, Marilu. / Genetics of soft tissue tumors. Modern Soft Tissue Pathology: Tumors and Non-Neoplastic Conditions. Cambridge University Press, 2010. pp. 105-126
@inbook{e8ac8c7fcd114c8fb551a1fcdfbfa15a,
title = "Genetics of soft tissue tumors",
abstract = "The evolution of mesenchymal tumor classification schemes has coincided with cytogenetic and molecular advances. Increasing recognition of the specific genetic abnormalities inherent in these tumors and the growing use of cytogenetic and molecular genetic procedures have aided in the formulation of a diagnosis and the resolution of cellular origin. Several of the genetic markers are also of prognostic value, and the importance of molecular testing for guiding targeted therapeutic strategies in mesenchymal neoplasia is emerging. The objective of this chapter is to review recurrent or tumor-specific genetic events in mesenchymal neoplasms and discuss the cytogenetic and molecular cytogenetic approaches commonly used in clinical practice to identify them. GENETIC EVENTS AND MOLECULAR PATHOLOGIC APPROACHES: Three common genetic approaches used to identify mesenchymal tumor-specific abnormalities include (1) conventional cytogenetic; (2) molecular cytogenetic (fluorescence in situ hybridization [FISH]); and, (3) reverse transcription-polymerase chain reaction (RT-PCR) analyses. Historically, many of the genetic abnormalities that have come to be recognized as tumor specific in sarcomas were first identified by conventional cytogenetic analysis.1 In turn, the initial cytogenetic evidence facilitated the cloning of many candidate genes involved in the pathogenesis of mesenchymal tumors. Cytogenetic analysis has provided clinicians with a valuable tool to supplement their diagnostic armamentarium. The addition of molecular cytogenetic (FISH) and molecular approaches (RT-PCR) has further enhanced the sensitivity and accuracy of detecting nonrandom chromosomal imbalances or structural rearrangements in sarcomas, including assessment in formalin-fixed, paraffin-embedded tissues.",
author = "Bridge, {Julia A.} and Marilu Nelson",
year = "2010",
month = "1",
day = "1",
doi = "10.1017/CBO9780511781049.005",
language = "English (US)",
isbn = "9780521874090",
pages = "105--126",
booktitle = "Modern Soft Tissue Pathology",
publisher = "Cambridge University Press",

}

TY - CHAP

T1 - Genetics of soft tissue tumors

AU - Bridge, Julia A.

AU - Nelson, Marilu

PY - 2010/1/1

Y1 - 2010/1/1

N2 - The evolution of mesenchymal tumor classification schemes has coincided with cytogenetic and molecular advances. Increasing recognition of the specific genetic abnormalities inherent in these tumors and the growing use of cytogenetic and molecular genetic procedures have aided in the formulation of a diagnosis and the resolution of cellular origin. Several of the genetic markers are also of prognostic value, and the importance of molecular testing for guiding targeted therapeutic strategies in mesenchymal neoplasia is emerging. The objective of this chapter is to review recurrent or tumor-specific genetic events in mesenchymal neoplasms and discuss the cytogenetic and molecular cytogenetic approaches commonly used in clinical practice to identify them. GENETIC EVENTS AND MOLECULAR PATHOLOGIC APPROACHES: Three common genetic approaches used to identify mesenchymal tumor-specific abnormalities include (1) conventional cytogenetic; (2) molecular cytogenetic (fluorescence in situ hybridization [FISH]); and, (3) reverse transcription-polymerase chain reaction (RT-PCR) analyses. Historically, many of the genetic abnormalities that have come to be recognized as tumor specific in sarcomas were first identified by conventional cytogenetic analysis.1 In turn, the initial cytogenetic evidence facilitated the cloning of many candidate genes involved in the pathogenesis of mesenchymal tumors. Cytogenetic analysis has provided clinicians with a valuable tool to supplement their diagnostic armamentarium. The addition of molecular cytogenetic (FISH) and molecular approaches (RT-PCR) has further enhanced the sensitivity and accuracy of detecting nonrandom chromosomal imbalances or structural rearrangements in sarcomas, including assessment in formalin-fixed, paraffin-embedded tissues.

AB - The evolution of mesenchymal tumor classification schemes has coincided with cytogenetic and molecular advances. Increasing recognition of the specific genetic abnormalities inherent in these tumors and the growing use of cytogenetic and molecular genetic procedures have aided in the formulation of a diagnosis and the resolution of cellular origin. Several of the genetic markers are also of prognostic value, and the importance of molecular testing for guiding targeted therapeutic strategies in mesenchymal neoplasia is emerging. The objective of this chapter is to review recurrent or tumor-specific genetic events in mesenchymal neoplasms and discuss the cytogenetic and molecular cytogenetic approaches commonly used in clinical practice to identify them. GENETIC EVENTS AND MOLECULAR PATHOLOGIC APPROACHES: Three common genetic approaches used to identify mesenchymal tumor-specific abnormalities include (1) conventional cytogenetic; (2) molecular cytogenetic (fluorescence in situ hybridization [FISH]); and, (3) reverse transcription-polymerase chain reaction (RT-PCR) analyses. Historically, many of the genetic abnormalities that have come to be recognized as tumor specific in sarcomas were first identified by conventional cytogenetic analysis.1 In turn, the initial cytogenetic evidence facilitated the cloning of many candidate genes involved in the pathogenesis of mesenchymal tumors. Cytogenetic analysis has provided clinicians with a valuable tool to supplement their diagnostic armamentarium. The addition of molecular cytogenetic (FISH) and molecular approaches (RT-PCR) has further enhanced the sensitivity and accuracy of detecting nonrandom chromosomal imbalances or structural rearrangements in sarcomas, including assessment in formalin-fixed, paraffin-embedded tissues.

UR - http://www.scopus.com/inward/record.url?scp=85012110479&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85012110479&partnerID=8YFLogxK

U2 - 10.1017/CBO9780511781049.005

DO - 10.1017/CBO9780511781049.005

M3 - Chapter

AN - SCOPUS:85012110479

SN - 9780521874090

SP - 105

EP - 126

BT - Modern Soft Tissue Pathology

PB - Cambridge University Press

ER -